Exploring Novel Mechanisms in Chronic Lymphocytic Leukemia

Jeff P. Sharman, MD, Medical Director for Hematology Research at The US Oncology Network, discusses the evolving treatment landscape for chronic lymphocytic leukemia (CLL). Dr. Sharman highlights key unmet needs in CLL management, including addressing resistance to standard therapies and improving outcomes for high-risk patient populations. He provides an in-depth overview of the current prognosis for CLL patients and how recent advancements are reshaping expectations. A significant focus of the discussion is on novel treatment options, such as pirtobrutinib, a next-generation BTK inhibitor designed to overcome resistance seen with earlier therapies. Dr. Sharman explains how this innovative therapy works, its potential benefits for patients, and its role in broadening the therapeutic arsenal against CLL.